Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Second Phase 3 Study of YERVOY™ (ipilimumab) in Metastatic Melanoma Meets Primary Endpoint of Overall Survival
Second Phase 3 Study of YERVOY™ (ipilimumab) in Metastatic Melanoma Meets Primary Endpoint of Overall Survival
Second Phase 3 Study of YERVOY™ (ipilimumab) in Metastatic Melanoma Meets Primary Endpoint of Overall Survival
Submitted by
admin
on June 5, 2011 - 10:45am
Source:
Yahoo/BusinessWire
News Tags:
Yervoy
Bristol-Myers Squibb
melanoma
Headline:
Second Phase 3 Study of YERVOY™ (ipilimumab) in Metastatic Melanoma Meets Primary Endpoint of Overall Survival
Do Not Allow Advertisers to Use My Personal information
